Introduction

Materials and Methods
1. Patient population
2. Study procedures
3. Statistical analyses
4. Ethical considerations

Results
1. Patients’ characteristics
Table 1.
Variable | Cohort A (n=400) | Cohort B (n=148) | p-value |
---|---|---|---|
Age, median (range, yr) | 64 (21-95) | 65 (33-89) | 0.582a) |
Sex | |||
Male | 248 (62.0) | 79 (53.4) | 0.078b) |
Female | 152 (38.0) | 69 (46.6) | |
BMI | 23.04±3.29 | 23.38±3.48 | 0.296a) |
No. of comorbidities | |||
0 | 196 (49.0) | 79 (53.4) | 0.139c) |
1 | 124 (31.0) | 49 (33.1) | |
≥ 2 | 80 (20.0) | 20 (13.5) | |
White blood cell count (/μL) | 6,058±2,137 | 5,951±1,791 | 0.560a) |
Hemoglobin (g/dL) | 12.6±1.8 | 12.4±2.1 | 0.274a) |
Platelet count (/μL) | 241±77 | 251±74 | 0.153a) |
D-dimer (μg/mL) | 0.92±1.80 | 0.94±1.60 | 0.894a) |
< 0.5 | 174 (43.5) | 67 (45.3) | 0.719c) (0.673d)) |
≥ 0.5 | 140 (35.0) | 59 (39.9) | |
Not checked | 86 (21.5) | 22 (14.9) | |
Tumor stage | |||
0-1 | 72 (18.0) | 37 (25.0) | 0.010a) |
2 | 83 (20.8) | 42 (28.4) | |
3 | 174 (43.5) | 55 (37.2) | |
4 | 71 (17.8) | 14 (9.5) | |
Tumor location | |||
Right colon cancere) | 80 (20.0) | 35 (23.6) | 0.296c) |
Left colon cancerf) | 147 (36.8) | 55 (37.2) | |
Rectal cancerg) | 173 (43.2) | 58 (39.2) | |
Histologic differentiation | |||
WDAC | 39 (9.8) | 16 (10.8) | 0.701c) |
MDAC | 319 (79.8) | 114 (77.0) | |
PDAC | 29 (7.2) | 11 (7.4) | |
Others | 13 (3.2) | 7 (4.7) | |
Preoperative treatment | |||
None | 344 (86.0) | 128 (86.5) | 0.935c) |
Chemotherapy | 14 (3.5) | 3 (2.0) | |
CCRT | 42 (10.5) | 17 (11.5) | |
Operation time (min) | 194.8±100.5 | 175.6±85.2 | 0.027a) |
Operation type | |||
Open | 121 (30.2) | 29 (19.6) | 0.013b) |
Laparoscopy | 279 (69.8) | 119 (80.4) |
Values are presented as number (%) or mean±standard deviation unless otherwise indicated. BMI, body mass index; WDAC, well differentiated adenocarcinoma; MDAC, moderately differentiated adenocarcinoma; PDAC, poorly differentiated adenocarcinoma; CCRT, concurrent chemoradiation therapy.
e) Right colon cancer included primary tumors located in the cecum, ascending colon, hepatic flexure, and transverse colon,
2. Postoperative VTE development in cohort A
Table 2.
Sex/Age (yr) | Comorbidity | Stage | Surgical procedure | Surgical outcome | Operation time (min) | VTE event | Time to VTE after surgery (day) | Treatment |
---|---|---|---|---|---|---|---|---|
M/63 | None | IIIC | Hartmann’s operation (open) | R0 | 445 | Asymptomatic PE | 15 | LMWH |
F/85 | DM, HTN | I | Anterior resection (laparoscopic) | R0 | 130 | Asymptomatic proximal DVT (left popliteal vein) | 8 | Observationa) |
F/73 | HTN | IVB | Abdominoperineal resection (laparoscopic) | R2 | 260 | Asymptomatic distal DVT (left calf vein) | 10 | Observationa) |
M/74 | HTN, CVA, dyslipidemia, dementia | IIIA | Subtotal colectomy (laparoscopic) | R0 | 235 | Asymptomatic distal DVT (right calf vein) | 7 | Observationa) |
M/77 | HTN, CKD | IIIC | Right hemicolectomy (laparoscopic) | R0 | 215 | Asymptomatic distal DVT (right calf vein) | 5 | Observationa) |
M/80 | CAD, COPD, asthma | IVA | Low anterior resection and hepatic metastasectomy (open) | R0 | 245 | Symptomatic distal DVT (bilateral leg edema, both calf veins) | 13 | LMWH |
M/75 | HTN | IIIC | Subtotal colectomy (open) | R0 | 200 | Asymptomatic proximal DVT (right superficial femoral vein) | 9 | LMWH |
M/66 | HTN, COPD | IIIB | Pelvic exenteration (open) | R0 | 825 | Asymptomatic proximal DVT (right superficial femoral vein) | 9 | LMWH |
M/72 | DM | IIA | Right hemicolectomy (laparoscopic) | R0 | 190 | Asymptomatic distal DVT (right calf vein) | 6 | Observationb) |
F/79 | HTN | I | Ultralow anterior resection (laparoscopic) | R0 | 185 | Asymptomatic distal DVT (right calf vein) | 5 | Observationb) |
F/80 | HTN | IIA | Right hemicolectomy (laparoscopic) | R0 | 100 | Asymptomatic distal DVT (left calf vein) | 8 | Observationb) |
F/82 | HTN, dyslipidemia | IVA | Abdominoperineal resection (open) | R2 | 165 | Asymptomatic distal DVT (left calf vein) | 8 | LMWH |
VTE, venous thromboembolisms; M, male; F, female; PE, pulmonary embolism; LMWH, low-molecular weight heparin; DM, diabetes mellitus; HTN, hypertension; DVT, deep vein thrombosis of the lower extremities; CVA, cerebrovascular accident; CKD, chronic kidney disease; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease.
3. Postoperative VTE development in cohort B
4. Univariate and multivariate analyses
Table 3.
Variable | VTE (–) (n=388) | VTE (+) (n=12) | p-value |
---|---|---|---|
Age (yr) | |||
< 70 | 252 (99.2) | 2 (0.8) | 0.001a) |
≥ 70 | 136 (93.2) | 10 (6.8) | |
Sex | |||
Male | 241 (97.2) | 7 (2.8) | 0.772a) |
Female | 147 (96.7) | 5 (3.3) | |
BMI, mean (kg/m2) | |||
< 25 | 297 (97.1) | 9 (2.9) | 1.000a) |
≥ 25 | 91 (96.8) | 3 (3.2) | |
No. of comorbidities | |||
0 | 195 (99.5) | 1 (0.5) | 0.001b) |
1 | 119 (96) | 5 (4) | |
≥ 2 | 74 (72.5) | 6 (7.5) | |
White blood cell count (/μL) | |||
≤ 10,000 | 369 (97.6) | 9 (2.4) | 0.023a) |
> 10,000 | 19 (86.4) | 3 (13.6) | |
Hemoglobin level (g/dL) | |||
< 10.0 | 32 (94.1) | 2 (5.9) | 0.271a) |
≥ 10.0 | 356 (97.3) | 10 (2.7) | |
Platelet count (/μL) | |||
≤ 400,000 | 375 (97.2) | 11 (2.8) | 0.352a) |
> 400,000 | 13 (92.9) | 1 (7.1) | |
D-dimer (μg/mL) | |||
< 0.5 | 173 (99.4) | 1 (0.6) | 0.003b) (0.006c)) |
≥ 0.5 | 131 (93.6) | 9 (6.4) | |
Not checked | 84 (97.7) | 2 (2.3) | |
Tumor stage | |||
0-1 | 70 (97.2) | 2 (2.8) | 0.614b) |
2 | 81 (97.6) | 2 (2.4) | |
3 | 169 (97.1) | 5 (2.9) | |
4 | 68 (95.8) | 3 (4.2) | |
Tumor location | |||
Right colon cancere) | 77 (96.2) | 3 (3.8) | 0.761b) |
Left colon cancerf) | 143 (97.3) | 4 (2.7) | |
Rectal cancerg) | 168 (97.1) | 5 (2.9) | |
Histologic differentiation | |||
WDAC | 39 (100) | 0 | 0.415b) |
MDAC | 309 (96.9) | 10 (3.1) | |
PDAC | 27 (93.1) | 2 (6.9) | |
Others | 13 (100) | 0 | |
Preoperative treatment | |||
None | 333 (96.8) | 11 (3.2) | 0.661b) |
Chemotherapy | 14 (100) | 0 | |
CCRT | 41 (97.6) | 1 (2.4) | |
Operation time (min) | 193±96 | 266±196 | 0.220d) |
Operation type | |||
Open | 117 (96.7) | 4 (3.3) | 0.759a) |
Laparoscopy | 271 (97.1) | 8 (2.9) | |
Surgical outcome | 0.648b) | ||
R0 | 341 (97.2) | 10 (2.8) | |
R1 or R2 | 47 (95.9) | 2 (4.1) |
Values are presented as number (%) or mean±standard deviation. VTE, venous thromboembolisms; BMI, body mass index; WDAC, well differentiated adenocarcinoma; MDAC, moderately differentiated adenocarcinoma; PDAC, poorly differentiated adenocarcinoma; CCRT, concurrent chemoradiation therapy.
e) Right colon cancer included primary tumors located in the cecum, ascending colon, hepatic flexure, and transverse colon,
Table 4.
Table 5.
All of the clinical parameters that were measured or examined preoperatively in this study were included. BMI, body mass index; WDAC, well differentiated adenocarcinoma; MDAC, moderately differentiated adenocarcinoma; PDAC, poorly differentiated adenocarcinoma; CCRT, concurrent chemoradiation therapy.

Discussion

Conclusion
